Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 37.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,199 shares of the company's stock after purchasing an additional 7,888 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Vaxcyte were worth $2,390,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in PCVX. CIBC Asset Management Inc increased its position in Vaxcyte by 3.6% during the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company's stock valued at $358,000 after buying an additional 110 shares in the last quarter. Smartleaf Asset Management LLC increased its position in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after buying an additional 260 shares in the last quarter. KBC Group NV increased its position in Vaxcyte by 13.6% during the 3rd quarter. KBC Group NV now owns 2,683 shares of the company's stock valued at $307,000 after buying an additional 322 shares in the last quarter. Amalgamated Bank increased its position in Vaxcyte by 8.6% during the 3rd quarter. Amalgamated Bank now owns 4,081 shares of the company's stock valued at $466,000 after buying an additional 322 shares in the last quarter. Finally, Whipplewood Advisors LLC acquired a new position in Vaxcyte during the 4th quarter valued at about $28,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 2.2 %

Shares of NASDAQ PCVX traded down $1.68 during midday trading on Thursday, hitting $74.46. The stock had a trading volume of 841,200 shares, compared to its average volume of 929,045. The company has a market capitalization of $9.59 billion, a PE ratio of -16.19 and a beta of 1.02. The stock has a 50 day simple moving average of $81.67 and a 200-day simple moving average of $94.28. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06.

Remove Ads

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on PCVX. Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Needham & Company LLC reissued a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $147.50.

Insider Activity

In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 46,250 shares of company stock worth $3,840,018 over the last quarter. 3.10% of the stock is currently owned by corporate insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.